Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 72.8%

Neg 0% Neu 0% Pos 72.8%

Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.